What IPMN Patients Reported: In-Depth Survey Findings

What IPMN Patients Reported: In-Depth Survey Findings

Imagine discovering a cyst in your pancreas and immediately fearing the worst — pancreatic cancer, a notoriously silent killer with low survival rates. Yet many pancreatic cysts, including intraductal papillary mucinous neoplasms (IPMNs), are discovered incidentally, often during imaging for unrelated reasons. Understanding their prevalence, progression, genetic associations, and patient experiences is crucial for early intervention and management. A recent survey of 122 individuals living with IPMNs provides unprecedented insight into demographics, cyst characteristics, diagnostic testing, and patient-reported history, highlighting patterns that may guide future research and clinical care.

IPMNs are mucin-producing cystic lesions of the pancreas that can involve the main duct, branch ducts, or both. While the majority of cases remain benign, a subset carries a risk of progressing to invasive pancreatic cancer, making careful monitoring essential. The survey included participants aged 32 to 78 at the time of data collection, with a median age of 61. Interestingly, the median age at diagnosis was 57, slightly younger than historical averages, suggesting earlier detection or population variability. Women comprised 84% of respondents, with men representing 16%, indicating a notable female predominance in this cohort, though prior literature suggests either equal distribution or slight female predominance. Racial distribution was predominantly White (93%), with smaller representations from Black, Asian, American Indian, and Native Hawaiian participants.

Body mass index (BMI) appeared relevant, with the cohort spanning from 12 to 59 and a median of 25, placing most participants in the overweight category. Obesity and higher BMI have been implicated in both IPMN prevalence and progression, potentially through metabolic and inflammatory pathways affecting pancreatic tissue. Survey results showed variability in the number of IPMNs per patient. At diagnosis, most had a single IPMN (71 participants), while others had multiple lesions. Over time, some patients reported an increase in cyst number, highlighting the progressive nature of this condition and the importance of longitudinal monitoring.

Cyst location varied within the pancreas. The head was the most common site (46.7%), followed by the body (45%), tail (44%), and neck (18%), acknowledging that patients may have multiple cysts. Cyst size ranged from 0.3 cm to 8 cm, with a median size of 1.2 cm and a mean of 1.6 cm. Branch duct IPMNs predominated (approximately 80%), followed by mixed type (12.3%) and main duct type (8.2%). Only a small fraction of cysts decreased in size over time, emphasizing the relative stability or slow growth of most lesions and the low likelihood of spontaneous regression.

Family history of pancreatic cancer was relatively uncommon, reported by 19 participants, while only six reported family history of IPMN, suggesting limited hereditary clustering. Genetic testing was performed in 33.6% of participants, providing insight into pathogenic mutations (e.g., BRCA2, ATM, PRSS1, NBN), likely pathogenic variants (e.g., KAS G12V, SDHA), variants of uncertain significance, and benign findings. Blood type analysis revealed a predominance of type A (35.2%), followed by O (31.1%), B (16.4%), and AB (7.4%), with 9.8% unsure of their blood type. Although some literature suggests increased pancreatic cancer risk in types A, B, and AB, the survey findings did not establish causation but provided a snapshot of patient characteristics.

Past medical history revealed gastrointestinal reflux disease (GERD) as the most common comorbidity (31%), followed by impaired glucose metabolism (25%), autoimmune conditions (22%), and hypertension (19%). Only 13% of participants reported no prior medical history. Notably, 66% had cysts in other organs, including kidney (44%), liver (42%), and ovarian (18%), higher than general population prevalence, raising questions about systemic cystic tendencies or shared etiological factors. Abdominal surgery was reported by 46 participants, including gallbladder (32), pancreas (10), stomach (3), and spleen (1). Complex surgeries such as Whipple procedures and distal pancreatectomies were documented, with postoperative outcomes generally positive, demonstrating feasibility even in older patients.

Diagnostic work-up included endoscopic ultrasound (EUS) in 55% of respondents, with fine-needle aspiration (FNA) performed in 38 participants. FNA cytology revealed benign findings in 12 cases, indeterminate or inconclusive results in 8, low-grade dysplasia in 2, and suspicious or potentially neoplastic lesions in 16, underscoring the limitations of cytology and the importance of combining imaging, molecular markers, and clinical judgment. Biomarker analysis such as CA 19-9, amylase, glucose, KRAS, and GNAS mutations further stratified lesion risk. Elevated CA 19-9 was rare, and lipase elevation occurred in 12% of patients, often corresponding to acute pancreatitis episodes rather than malignancy. These findings emphasize that no single marker reliably predicts malignancy, reinforcing the need for multi-modal assessment.

The survey also assessed lifestyle factors and medication use. Only 26% reported a history of smoking, 41% consumed alcohol, and long-term medication exposure (>5 years) included thyroid hormone (13 participants), statins (12), metformin (10), beta-blockers (9), and proton pump inhibitors (9). No specific medication appeared to universally contribute to IPMN development, highlighting the multifactorial nature of cyst pathogenesis.

Patient experiences provided insight into symptomatology. While IPMNs are often asymptomatic, 25% reported postprandial abdominal pain, 16% constant pain, and 7% fasting pain. Despite these complaints, 56% of participants reported no gastrointestinal pain, reflecting the silent nature of many pancreatic cysts. This asymptomatic course underscores the importance of surveillance, particularly in patients with risk factors such as family history, metabolic disorders, or previous abdominal surgery.

Early detection is critical for management. Regular imaging, including MRI, CT, or EUS, allows monitoring of cyst growth, morphology, and potential high-risk features. Patients with suspicious characteristics — rapid growth, main duct involvement, mural nodules, or concerning molecular markers — may require surgical intervention, while stable, low-risk branch duct IPMNs can often be managed conservatively. Understanding lesion biology, patient comorbidities, and personal preferences informs individualized treatment strategies, balancing the risks of surgery against the natural history of the cyst.

Survey data demonstrate that IPMN is a heterogeneous condition with variable progression, highlighting the need for personalized monitoring plans. Most lesions remain stable, a minority grow or develop concerning features, and spontaneous regression is rare. Integrating cytology, biomarkers, imaging, and patient history provides the best predictive framework for malignant transformation, emphasizing the necessity for comprehensive follow-up in all patients diagnosed with IPMN.

In conclusion, the survey of 122 patients with IPMN offers a detailed portrait of demographics, cyst characteristics, genetic markers, comorbidities, and lifestyle factors. While most cysts are benign and asymptomatic, vigilant monitoring using imaging, molecular analysis, and clinical evaluation is essential to identify high-risk lesions early. Surgical intervention remains effective for lesions with concerning features, and outcomes are generally favorable, even in older adults. Awareness, education, and proactive management empower patients to navigate IPMN safely, optimize monitoring, and reduce the risk of progression to pancreatic cancer. Early detection and tailored care remain the pillars of effective IPMN management, ensuring that individuals live informed, empowered, and healthier lives .